What is the severity of CVE-2014-6522?

CVE-2014-6522 has been rated as a medium severity vulnerability due to its potential impact on integrity.

How do I fix CVE-2014-6522?

To fix CVE-2014-6522, update your Oracle Fusion Middleware to the latest version that addresses this vulnerability.

Which versions of Oracle Fusion Middleware are affected by CVE-2014-6522?

CVE-2014-6522 affects Oracle Fusion Middleware versions 11.1.1.7, 11.1.2.4, 12.1.2.0, and 12.1.3.0.

What types of attacks exploit CVE-2014-6522?

CVE-2014-6522 can be exploited by remote attackers to affect the integrity of applications using ADF Faces.

Is there a workaround for CVE-2014-6522?

There are no official workarounds for CVE-2014-6522, and updating to a patched version is recommended.

Vulnerability/
CVE-2014-6522

medium

4.3

15/10/2014

6/8/2024

CVE-2014-6522

First published: Wed Oct 15 2014(Updated: )

Unspecified vulnerability in the Oracle JDeveloper component in Oracle Fusion Middleware 11.1.1.7, 11.1.2.4, 12.1.2.0, and 12.1.3.0 allows remote attackers to affect integrity via vectors related to ADF Faces.

Credit: secalert_us@oracle.com

Affected Software	Affected Version	How to fix
Oracle Fusion Middleware	=11.1.1.7.0
Oracle Fusion Middleware	=11.1.2.4.0
Oracle Fusion Middleware	=12.1.2.0.0
Oracle Fusion Middleware	=12.1.3.0.0

Remedy

http://www.oracle.com/technetwork/topics/security/cpuoct2014-1972960.html

Never miss a vulnerability like this again

Reference Links

Frequently Asked Questions

What is the severity of CVE-2014-6522?
CVE-2014-6522 has been rated as a medium severity vulnerability due to its potential impact on integrity.
How do I fix CVE-2014-6522?
To fix CVE-2014-6522, update your Oracle Fusion Middleware to the latest version that addresses this vulnerability.
Which versions of Oracle Fusion Middleware are affected by CVE-2014-6522?
CVE-2014-6522 affects Oracle Fusion Middleware versions 11.1.1.7, 11.1.2.4, 12.1.2.0, and 12.1.3.0.
What types of attacks exploit CVE-2014-6522?
CVE-2014-6522 can be exploited by remote attackers to affect the integrity of applications using ADF Faces.
Is there a workaround for CVE-2014-6522?
There are no official workarounds for CVE-2014-6522, and updating to a patched version is recommended.

collector/nvd-index
agent/type
agent/references
agent/softwarecombine
collector/mitre-cve
source/MITRE
agent/remedy
agent/last-modified-date
agent/severity
agent/author
agent/tags
agent/first-publish-date
agent/description
agent/event
agent/source
vendor/oracle
canonical/oracle fusion middleware
version/oracle fusion middleware/11.1.1.7.0
version/oracle fusion middleware/11.1.2.4.0
version/oracle fusion middleware/12.1.2.0.0
version/oracle fusion middleware/12.1.3.0.0

Company

Resources

Contact

SecAlerts Pty Ltd.
132 Wickham Terrace
Fortitude Valley,
QLD 4006, Australia
info@secalerts.co

By using SecAlerts services, you agree to our services end-user license agreement. This website is safeguarded by reCAPTCHA and governed by the Google Privacy Policy and Terms of Service. All names, logos, and brands of products are owned by their respective owners, and any usage of these names, logos, and brands for identification purposes only does not imply endorsement. If you possess any content that requires removal, please get in touch with us.

Frequently Asked Questions

What is the severity of CVE-2014-6522?
CVE-2014-6522 has been rated as a medium severity vulnerability due to its potential impact on integrity.
How do I fix CVE-2014-6522?
To fix CVE-2014-6522, update your Oracle Fusion Middleware to the latest version that addresses this vulnerability.
Which versions of Oracle Fusion Middleware are affected by CVE-2014-6522?
CVE-2014-6522 affects Oracle Fusion Middleware versions 11.1.1.7, 11.1.2.4, 12.1.2.0, and 12.1.3.0.
What types of attacks exploit CVE-2014-6522?
CVE-2014-6522 can be exploited by remote attackers to affect the integrity of applications using ADF Faces.
Is there a workaround for CVE-2014-6522?
There are no official workarounds for CVE-2014-6522, and updating to a patched version is recommended.